Showing results (491-500 of 526) with videos related to

Sort By:
Pageof 53
Nature Cancer|February 11, 2021
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencingSara Parsa, Ana Ortega-Molina, Hsia-Yuan Ying, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|January 12, 2021
Effects of Prolonged Dual Antiplatelet Therapy in ST-Segment Elevation vs. Non-ST-Segment Elevation Myocardial InfarctionJihoon Kim, Young Bin Song, Ju-Hyeon Oh, et al.
Medrxiv : the Preprint Server for Health Sciences|July 16, 2021
Next-generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody RepertoireRafael D Melani, Benjamin J Des Soye, Jared O Kafader, et al.
Circulation. Cardiovascular Interventions|May 2, 2020
Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized TrialKi Hong Choi, Young Bin Song, Joo Myung Lee, et al.
Science Advances|December 9, 2022
Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemiaQi Jin, Blanca Gutierrez Diaz, Tim Pieters, et al.
Lancet (London, England)|March 17, 2018
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trialJoo-Yong Hahn, Young Bin Song, Ju-Hyeon Oh, et al.
Journal of Proteome Research|December 8, 2021
Next-Generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody RepertoireRafael D Melani, Benjamin J Des Soye, Jared O Kafader, et al.
Journal of the American Chemical Society|February 18, 2020
Two Distinct Mechanisms of Inhibition of LpxA Acyltransferase Essential for Lipopolysaccharide BiosynthesisWooseok Han, Xiaolei Ma, Carl J Balibar, et al.
Korean Circulation Journal|May 30, 2015
Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patientsJi-Yong Jang, Sang-Hak Lee, Byung Soo Kim, et al.
Clinical Therapeutics|September 14, 2025
Efficacy and Safety of Fimasartan, Atorvastatin, and Ezetimibe Combination Therapy in Patients With Hypertension and Dyslipidemia: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical TrialSoon Jun Hong, Ju Hyeon Kim, Kwang Soo Cha, et al.
Pageof 53